Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-557-0 | CAS number: 12286-65-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 21th July 2021 to 8th November 2021
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- 2016
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell gene mutation test using the Hprt and xprt genes
Test material
- Reference substance name:
- Calcium bis[3-nitro-4-[[2-oxo-1-[(phenylamino)carbonyl]propyl]azo]benzenesulphonate]
- EC Number:
- 235-557-0
- EC Name:
- Calcium bis[3-nitro-4-[[2-oxo-1-[(phenylamino)carbonyl]propyl]azo]benzenesulphonate]
- Cas Number:
- 12286-65-6
- Molecular formula:
- C16H14N4O7S.1/2Ca
- IUPAC Name:
- calcium bis(3-nitro-4-{[2-oxo-1-(phenylcarbamoyl)propyl]diazenyl}benzenesulfonate)
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- Batch No. 20A829
Method
Species / strain
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Metabolic activation system:
- The metabolic activation was performed by S9 fraction of rat liver homogenate and mixture of cofactors.
The liver homogenate was prepared from Wistar male rats weighing approximately
200 g, previously induced with Delor 106 (a mixture of PCBs). Delor 106 was diluted with olive oil to a concentration of 200 mg·mL-1, and each rat was administered a single injection
of 500 mg.kg-1 5 days before S9 preparation. The S9 was prepared according to the methods described by Maron and Ames (1). The liver was removed from each animal and washed in ice cold 0.15 M KCl. The livers washed were mixed with another 0.15 M KCl (3 mL·g-1 wet liver) homogenized in a grinder, and the tissue suspension was centrifuged for 10 min at 9000 g. Aliquots of the supernatant (S9) were stored in plastic tubes using sterile technique
at a temperature below –70 C.
Every lot of S9 was tested for sterility and activity in the Ames test with the aid of bacterial strain TA 98 according to internal SOP M/12. Activity was within expected limits.
Cofactors (NADP and glucoso-6-phosphate) were dissolved in PBS. Composition of S9 mix was as follows:
S9 mix composition:
S9 tissue fraction……………………………….….1.0 mL
NADP (0.1M) ..……………………………………0.4 mL
G-6-P (0.1M)…………………………….………...0.5 mL
KC1 (0.33M)……………………………….……...1.0 mL
MgCl2 (0.lM)………………………………………0.5 mL
Phosphate Buffer (0.2 M)……..…………………. 4.6 mL
8.0 mL
Each plate in all experiments with metabolic activation contained 4.0 mL of S9mix, 5.0 mL
of complete medium and 1.0 mL of the test item solution in DMEM. - Test concentrations with justification for top dose:
- Concentrations used as maximum for cytotoxicity test with and without metabolic activation were 0.001, 0.0025, 0.005, 0.01, 0.025 and 0.05 mg per mL.
Minor changes in cells appearance and no cytotoxicity was observed in the experiment without neither in the experiment with metabolic activation. Therefore, one higher concentration was used for mutagenicity testing and concentrations used for the mutagenicity experiments were 0.01, 0.025, 0,05 and 0.1 mg per mL. - Vehicle / solvent:
- DMSO
- Details on test system and experimental conditions:
- Cells V79
The lung fibroblasts V79 from male Chinese hamster were used for testing.
Frozen permanent cell cultures were obtained from European Collection of Cell Cultures (ECACC). V79 used for experiments: Lot. No.: 15H003. ECACC Certificates of Analysis are a part of archived study documentation. Sponsor declared identity, sterility and absence of Mycoplasma in provided cultures.
The cells were kept at -196 ºC under liquid nitrogen. After activation, cells were grown
in the same complete medium as used for growing of cultures (10 % FBS, an in incubator (5 % CO2, 37±1 °C, moistened).
Cells underwent maximum 5 passages after thawing the original culture delivered
from cell collection before using for mutagenicity testing.
Cleansing of cultures was performed 5 days before treatment with complete medium supplemented with HAT supplement due to elimination of mutants.
Mycoplasma Determination
Cell cultures were checked for mycoplasma contamination. At every experiment, one withdrawal of media has been performed and sent to the contract laboratory performing mycoplasma determination. - Rationale for test conditions:
- Solubility
The test item is very little soluble in water. Sponsor declared solubility 18 mg per litre what is 0.018 mg per ml.
In the previously performed bacterial reverse mutation, test item solubility in DMSO was about 4 mg per mL (4000 µg per mL). Since after addition to Petri dishes (PD) the concentration is reduced by 100 times (only 1% DMSO concentration is allowed), the maximum possible concentration on the Petri dishes would be around 40 μg per mL.
Final concentration in Petri dishes would be then similar as in water solvent DMEM.
It was intended to test cytotoxicity with test item diluted in both water and DMSO. In DMSO, application forms had to be 100 times more concentrated in DMEM and 10 times more concentrated than the resulting concentration on Petri dishes.
Since the 10 times more concentrated suspension in water could not be prepared, the toxicity test was finally carried out only with the test item prepared as a suspension in the DMSO.
Cytotoxicity
The cytotoxicity experiment was performed with and without metabolic activation. The nominal concentrations for cytotoxicity experiment were 0.001, 0.0025, 0.005, 0.01, 0.025, and 0.05 mg per mL.
As either, the maximum concentration used was not toxic and did not cause precipitation in Petri dishes, 0.1 mg per mL was used as maximum for the mutagenicity experiment without metabolic activation. At the same time, a metabolic activation cytotoxicity test was performed which found that the concentration of 0.1 mg per mL was not toxic.
Mutation Assay Procedure
Nominal concentrations for the mutagenicity experiments were 0.01, 0.025, 0.05 and 0.1 mg per mL and were the same for experiments with as well as without metabolic activation. - Evaluation criteria:
- Assay Acceptability Criteria
1) Concurrent negative controls should be within 95 % of the control values distribution (mean±SD) of the laboratory’s historical negative control database.
Historical control range is 0.11-2.83 mutants per 105cells (167 entries).
2) Concurrent positive controls should induce responses that are compatible with those generated in the historical positive control database and produce a statistically significant increase compared with the concurrent negative control.
3.0– 48.90 mutants per 105 cells for dimethylbenzanthracene (78 entries),
5.29– 24.15 mutants per 105 cells for EMS 5mM solution (51 entries),
11.51 – 48.71 mutants per 105 cells for EMS 10mM solution (52 entries).
3) Two experimental conditions (i.e., with and without metabolic activation) were tested unless one resulted in positive results.
4) Adequate number of cells is used (minimum 2 million for treatment/passage) and concentrations are analysable.
Evaluation of Results
Each experiment is evaluated separately using modified two-fold increase rule according to Claxton L.D. et al, Mutat. Res.,189, 83-91, 1987 (2).
The mutagenic potential is indicated by increasing number of mutants in treated groups in comparison to the negative solvent control (modified two-fold increase rule and any of the results outside the distribution of the historical negative control data) and/or by dependence of increasing number of mutants on dose (dose-response relationship).
There is no requirement for verification of a clearly positive or negative response.
In cases when the response is neither clearly negative nor clearly positive than a repeat experiment possibly using modified experimental conditions (e.g., concentration spacing, other metabolic activation conditions i.e., S9 concentration or S9 origin) could be performed.
Results and discussion
Test results
- Key result
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- 4.1. Solubility
The test item was dissolved in DMSO. The application forms, which had to be 100 more concentrated than the final concentration on the Peri dishes, were all homogeneous suspensions in DMSO.
0.1 ml of such prepared application form was added to 9.9 mL of complete medium. No precipitation was observed on the dishes at any concentration
Analogous concentrations of the test item were therefore prepared in test tubes. It was found that a concentration of 0.05 mg per ml caused almost imperceptible precipitation, and a concentration of 0.1 mg per ml caused clear precipitation in the medium. After 3 hours in test tubes, the test item fell to the bottom and could not be shaken to a homogeneous state.
4.2. Cytotoxicity
4.2.1. Cytotoxicity Experiment
Concentrations 0.001, 0.0025, 0.005, 0.01, 0.025 and 0.05 mg per mL were used for the cytotoxicity experiment with and without metabolic activation.
Minor changes at appearance of cells (slight shorten of cells) were observed in the end of treatment in the experiment without and with metabolic activation starting from 0.01 mg per mL. The RS value varied from 76.2 to 115.5% in the experiment without metabolic activation and from 81.5 to 121.8% in the experiment with metabolic activation. For results see Tables 2 and 3.
No precipitation in PM at any concentration was observed in the cytotoxicity test. Therefore, these treatment solutions (suspensions) were prepared in tubes where precipitation could be better observed.
In the test tubes it was found, that in concentration of 0.05 mg per mL precipitation was almost imperceptible. In the concentration of 0.1 mg per mL plain precipitation was perceptible. After 3 hours the test item settled to the bottom, so that it could no longer be fuzzed. We assume that the same phenomenon occurred on the dishes. However, when examining the dishes under a microscope, nothing of the that was found, and the medium did not appear cloudy.
Based on the cytotoxicity test, the following concentrations were determined for mutagenicity testing: 0.01, 0.025; 0.05; and 0.1 mg per mL.
4.2.2. Cytotoxicity in Mutagenicity Experiments
Concentrations used for mutagenicity experiments come from the previous cytotoxicity experiments. Results are given in Tables 4 and 5.
No precipitation was observed in any concentration.
Minor changes at appearance of cells (slight shorten of cells) were observed in the end of treatment in the experiment without and with metabolic activation in all concentrations. The RS value varied from 68.7 to 98.7% in the experiment without metabolic activation and from 70.7 to 91.5% in the experiment with metabolic activation.
The reduction in MS was caused to dilution errors rather than cytotoxicity of the test item because it was not dose dependent. For results see Tables 4, 5.
4.6. Mutagenicity Experiments
Mutagenicity results are given in tables 10-11, containing numbers of colonies in Petri dishes for plating efficiency, its average values and PE, number of mutants in single plates, number of planted cells, mutation frequency and ratio of number of mutants in test concentration vs number of mutants in solvent control.
Notes to tables and figures:
NC negative control (medium only)
DMSO solvent control
CGM complete growth medium
Conc. concentration
avg average value
NE not evaluable
PE plating efficiency
Adj. CE adjusted cloning efficiency
RS relative survival
NSC number of survived cells
∑M sum of mutants in all 5 dishes
NPC number of planted cells
∑NPC sum of planted cell in one concentration
MF/105 cells mutation frequency
Mt/Msc number of mutants in test concentration vs number of mutants in solvent control
Msc average value mutation frequency of both NCs
1,94 text written with cursive letters – replicate with less than 2*106 cells
EMS50 ethylmethansulphonate 50 µL
EMS100 ethylmethansulphonate 100 µL
(1), (2) replicate 1 or 2
add additional experiment
NCS*104 number of cells in suspension after trypsinization *104
Expression time a period from treatment to extraction of mutants
Any other information on results incl. tables
Table 2: Cytotoxicity experiment without metabolic activation
Conc. (mg per mL) | RS early (%) | Late survival | RS (%) | ||||
Count of colonies | avg | RS late (%) | |||||
NC | 85.5 | 381 | 360 | 400 | 380 | 103.2 | 88.2 |
DMSO | 100.0 | 384 | 354 | 368 | 369 | 100.0 | 100.0 |
0.0010 | 74.3 | 528 | 549 | 562 | 546 | 148.2 | 110.1 |
0.0025 | 113.7 | 342 | 373 | 375 | 363 | 98.6 | 112.0 |
0.0050 | 84.2 | 362 | 381 | 257 | 333 | 90.4 | 76.2 |
0.0100 | 117.8 | 304 | 302 | 301 | 302 | 82.0 | 96.6 |
0.0250 | 155.6 | 269 | 286 | 255 | 270 | 73.2 | 114.0 |
0.0500 | 128.6 | 333 | 321 | 339 | 331 | 89.8 | 115.5 |
Table 3: Cytotoxicity experiment with metabolic activation
Conc. (mg per mL) | RS early (%) | Late survival | RS (%) | ||||
Count of colonies | avg | RS late (%) | |||||
NC | 118.8 | 325 | 309 | 311 | 315 | 85.4 | 101.5 |
DMSO | 100.0 | 384 | 354 | 368 | 369 | 100.0 | 100.0 |
0.0010 | 111.1 | 318 | 349 | 323 | 330 | 89.5 | 99.4 |
0.0025 | 107.2 | 417 | 399 | 440 | 419 | 113.6 | 121.8 |
0.0050 | 97.6 | 360 | 368 | 349 | 359 | 97.4 | 95.0 |
0.0100 | 102.9 | 315 | 292 | 324 | 310 | 84.2 | 86.6 |
0.0250 | 99.5 | 315 | 303 | 288 | 302 | 81.9 | 81.5 |
0.0500 | 90.9 | 381 | 365 | 403 | 383 | 103.9 | 94.4 |
0.1000 | 87.4 | 220 | 218 | 283 | 240 | 110.2 | 95.8 |
Table 4: Cytotoxicity in mutagenicity experiment without metabolic activation
Concentration (mg per mL) | RS early (%) | Late survival | RS (%) | avg RS (%) | ||||
Count of colonies | avg | RS late (%) | ||||||
NC (1) | 68.6 | 302 | 273 | 267 | 281 | 128.7 | 87.8 | 87.8 |
DMSO (1) | 87.9 | 197 | 210 | 215 | 207 | 95.1 | 83.1 | 100.0 |
DMSO (2) | 112.1 | 239 | 233 | 214 | 229 | 104.9 | 116.9 | |
0.01 (1) | 70.5 | 238 | 223 | 257 | 239 | 109.8 | 77.0 | 68.7 |
0.01 (2) | 57.0 | 245 | 222 | 231 | 233 | 106.7 | 60.5 | |
0.025 (1) | 54.6 | 211 | 202 | 262 | 225 | 103.2 | 56.0 | 73.3 |
0.025 (2) | 71.0 | 263 | 292 | 285 | 280 | 128.4 | 90.7 | |
0.05 (1) | 75.8 | 230 | 209 | 187 | 209 | 95.7 | 72.2 | 71.2 |
0.05 (2) | 60.9 | 247 | 251 | 261 | 253 | 116.1 | 70.2 | |
0.1 (1) | 87.4 | 236 | 286 | 274 | 265 | 121.7 | 105.8 | 98.7 |
0.1 (2) | 83.6 | 209 | 198 | 186 | 198 | 90.7 | 91.6 |
Table 5: Cytotoxicity in mutagenicity experiment with metabolic activation
Concentration (mg per mL) | RS early (%) | Late survival | RS (%) | avg RS (%) | ||||
Count of colonies | avg | RS late (%) | ||||||
NC (1) | 99.3 | 250 | 207 | 221 | 226 | 72.1 | 70.6 | 70.6 |
DMSO (1) | 113.0 | 337 | 381 | 324 | 347 | 110.9 | 123.5 | 100.0 |
DMSO (1) | 87.0 | 291 | 276 | 271 | 279 | 89.1 | 76.5 | |
0.01 (1) | 72.9 | 253 | 246 | 255 | 251 | 80.2 | 57.7 | 70.7 |
0.01 (2) | 93.8 | 282 | 274 | 295 | 284 | 90.5 | 83.7 | |
0.025 (1) | 110.9 | 270 | 233 | 279 | 261 | 83.2 | 90.9 | 91.5 |
0.025 (2) | 100.4 | 293 | 294 | 287 | 291 | 93.0 | 92.1 | |
0.05 (1) | 103.7 | 220 | 223 | 228 | 224 | 71.4 | 73.0 | 90.1 |
0.05 (2) | 146.5 | 238 | 234 | 225 | 232 | 74.1 | 107.1 | |
0.1 (1) | 140.8 | 203 | 210 | 239 | 217 | 69.4 | 96.3 | 83.4 |
0.1 (2) | 113.6 | 208 | 200 | 184 | 197 | 63.0 | 70.5 |
Table 10: Mutagenicity without metabolic activation, 3-hour treatment
Conc. (mg/mL) | Viability (number of colonies) | avg | PE (%) | Mutants (number of colonies) | ∑M | NPC | MF/105 cells | Mt/Msc | |||||||||||
NC (1) | 266 | 410 | 395 | 357 | 100.4 | 1 | 2 | 2 | 3 | 3 | 0 | 4 | 2 | 2 | 2 | 21 | 2,618,000 | 0.80 | 0.72 |
DMSO (1) | 390 | 395 | 387 | 391 | 109.9 | 2 | 5 | 3 | 2 | 4 | 4 | 1 | 4 | 4 | 5 | 34 | 2,864,889 | 1.19 | 1.07 |
DMSO (2) | 288 | 315 | 358 | 320 | 90.1 | 2 | 2 | 1 | 0 | 3 | 4 | 3 | 2 | 2 | 5 | 24 | 2,349,111 | 1.02 | 0.92 |
0.01 (1) | 322 | 345 | 363 | 343 | 96.6 | 0 | 0 | 1 | 2 | 4 | 3 | 1 | 1 | 2 | 4 | 18 | 2,517,778 | 0.71 | 0.64 |
0.01 (2) | 305 | 298 | 351 | 318 | 89.5 | 3 | 2 | 1 | 2 | 4 | 0 | 1 | 2 | 0 | 3 | 18 | 2,332,000 | 0.77 | 0.69 |
0.025 (1) | 357 | 357 | 361 | 358 | 100.8 | 2 | 3 | 3 | 4 | 1 | 4 | 4 | 4 | 2 | 8 | 35 | 2,627,778 | 1.33 | 1.20 |
0.025 (2) | 335 | 358 | 362 | 352 | 98.9 | 6 | 1 | 6 | 6 | 1 | 3 | 2 | 3 | 4 | 3 | 35 | 2,578,889 | 1.36 | 1.22 |
0.05 (1) | 410 | 381 | 366 | 386 | 108.5 | 8 | 4 | 4 | 4 | 7 | 0 | 0 | 4 | 4 | 4 | 39 | 2,828,222 | 1.38 | 1.24 |
0.05 (2) | 330 | 309 | 325 | 321 | 90.4 | 3 | 3 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 15 | 2,356,444 | 0.64 | 0.57 |
0.1 (1) | 362 | 357 | 365 | 361 | 101.6 | 2 | 5 | 3 | 2 | 5 | 4 | 6 | 1 | 4 | 4 | 36 | 2,649,778 | 1.36 | 1.22 |
0.1 (2) | 320 | 355 | 337 | 337 | 94.9 | 3 | 4 | 2 | 2 | 3 | 3 | 1 | 2 | 2 | 5 | 27 | 2,473,778 | 1.09 | 0.98 |
EMS50 | 390 | 413 | 389 | 397 | 111.8 | 44 | 44 | 32 | 36 | 44 | 35 | 33 | 47 | 37 | 54 | 406 | 2,913,778 | 13.93 | 12.53 |
EMS100 | 335 | 351 | 344 | 343 | 96.6 | 86 | 93 | 87 | 72 | 77 | 81 | 76 | 76 | 82 | 63 | 793 | 2,517,778 | 31.50 | 28.31 |
Table 11: Mutagenicity with metabolic activation, 3-hour treatment
Conc. (mg/mL) | Viability (number of colonies) | avg | PE (%) | Mutants (number of colonies) | ∑M | NPC | MF/105 cells | Mt/Msc | |||||||||||
NC (1) | 227 | 213 | 222 | 221 | 71.3 | 1 | 1 | 4 | 3 | 2 | 2 | 1 | 3 | 3 | 2 | 22 | 2,353,778 | 0.93 | 0.88 |
DMSO (1) | 355 | 302 | 328 | 328 | 106.0 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 3 | 20 | 2,407,778 | 0.83 | 0.79 |
DMSO (2) | 270 | 300 | 303 | 291 | 94.0 | 4 | 1 | 5 | 4 | 1 | 2 | 3 | 2 | 1 | 5 | 28 | 2,13,4000 | 1.31 | 1.24 |
0.01 (1) | 280 | 270 | 276 | 275 | 88.9 | 1 | 2 | 3 | 4 | 2 | 1 | 2 | 4 | 1 | 0 | 20 | 2,019,111 | 0.99 | 0.94 |
0.01 (2) | 341 | 396 | 378 | 372 | 120.0 | 3 | 3 | 5 | 1 | 4 | 2 | 8 | 3 | 5 | 4 | 38 | 2,725,556 | 1.39 | 1.32 |
0.025 (1) | 305 | 238 | 277 | 273 | 88.3 | 2 | 7 | 5 | 2 | 3 | 3 | 3 | 1 | 2 | 1 | 29 | 2,004,444 | 1.45 | 1.37 |
0.025 (2) | 353 | 316 | 325 | 331 | 107.0 | 2 | 1 | 6 | 1 | 2 | 2 | 1 | 1 | 6 | 7 | 29 | 2,429,778 | 1.19 | 1.13 |
0.05 (1) | 313 | 340 | 313 | 322 | 104.0 | 1 | 2 | 5 | 1 | 5 | 0 | 3 | 2 | 0 | 1 | 20 | 2,361,333 | 0.85 | 0.80 |
0.05 (2) | 326 | 299 | 307 | 311 | 100.3 | 5 | 1 | 4 | 2 | 2 | 5 | 2 | 6 | 4 | 4 | 35 | 2,278,222 | 1.54 | 1.45 |
0.1 (1) | 352 | 368 | 399 | 373 | 120.5 | 2 | 2 | 4 | 3 | 2 | 1 | 4 | 2 | 7 | 3 | 30 | 2,735,333 | 1.10 | 1.04 |
0.1 (2) | 275 | 255 | 267 | 266 | 85.8 | 2 | 1 | 1 | 5 | 4 | 7 | 1 | 6 | 3 | 2 | 32 | 1,948,222 | 1.64 | 1.55 |
DMBA(1) | 338 | 342 | 382 | 354 | 114.3 | 127 | 125 | 123 | 110 | 139 | 123 | 129 | 138 | 130 | 122 | 1 266 | 2,596,000 | 48.77 | 46.14 |
DMBA(2) | 379 | 352 | 353 | 361 | 116.7 | 94 | 93 | 94 | 91 | 90 | 91 | 89 | 109 | 96 | 98 | 945 | 2,649,778 | 35.66 | 33.74 |
Applicant's summary and conclusion
- Conclusions:
- Under the experimental conditions indicated above, the test item, Pigment Yellow 61, was non-mutagenic for V79 cells in experiments with and without metabolic activation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
